Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity
Science Advances · 24.01.2025 · 11 (4)
DOI: 10.1126/sciadv.ads3403 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 24.01.2025. Verfasst von Kristen C Vogt und 7 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Hauptthemen laut MEDLINE: Tumor Microenvironment, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Neoplasms. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCI NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
A major limiting factor in the success of chimeric antigen receptor (CAR) T cell therapy for the treatment of solid tumors is targeting tumor antigens also found on normal tissues. CAR T cells against GD2 induced rapid, fatal neurotoxicity because of CAR recognition of GD2 + normal mouse brain tissue. To improve the selectivity of the CAR T cell, we engineered a synthetic Notch receptor that selectively expresses the CAR upon binding to P-selectin, a cell adhesion protein overexpressed in tumor neovasculature. These tumor microenvironment actuated T (MEAT) cells ameliorated T cell infiltration in the brain, preventing fatal neurotoxicity while maintaining antitumor efficacy. We found that conditional CAR expression improved the persistence of tumor-infiltrating lymphocytes because of enhanced metabolic fitness of MEAT cells and the infusion of a less differentiated product. This approach increases the repertoire of targetable solid tumor antigens by restricting CAR expression and subsequent killing to cancer cells only and provides a proof-of-concept model for other targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY 10065, USA.
- Tri-Institutional PhD Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- Pharmacology Program, Weill Cornell Medicine, New York, NY 10065, USA.
- BCMB Program, Weill Cornell Medicine, New York, NY 10065, USA.
- Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA.
ORCID-Profile: Kristen C Vogt, Pedro C Silberman, Qianqian Lin, Daniel A Heller, David A Scheinberg
Förderung
- NIGMS NIH HHS
- NCI NIH HHS
- NINDS NIH HHS
Zitieren
APA
Vogt, K. C., Silberman, P. C., Lin, Q., Han, J. E., Laflin, A., Gellineau, H. A., Heller, D. A., & Scheinberg, D. A. (2025). Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity. Science Advances, 11(4). https://doi.org/10.1126/sciadv.ads3403
Vancouver
Vogt KC, Silberman PC, Lin Q, Han JE, Laflin A, Gellineau HA, et al. Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity. Science Advances. 2025;11(4). doi:10.1126/sciadv.ads3403
BibTeX
@article{Vogt2025,
author = {Vogt, Kristen C and Silberman, Pedro C and Lin, Qianqian and Han, James E and Laflin, Amy and Gellineau, Hendryck A and Heller, Daniel A and Scheinberg, David A},
title = {Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {4},
doi = {10.1126/sciadv.ads3403}
}
EUVIMED